Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.32 |
| ▸ | PPARG | P37231 | 1/20 | 0.32 |
| ▸ | MAPK10 | P53779 | 1/20 | 0.32 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.32 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.32 |
| ▸ | RXFP1 | Q9HBX9 | 1/20 | 0.32 |
| ▸ | NCOR2 | Q9Y618 | 1/20 | 0.32 |
| ▸ | CHRNA7 | P36544 | 3/20 | 0.31 |
| ▸ | HTR3A | P46098 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL763215 | 0.89 | OPRK1 (0.31) | ALDH1A1PPARGMAPK10KMT2ANPSR1 | |
| SCHEMBL15929815 | 0.89 | HTR3A (0.36) | ALDH1A1PPARGMAPK10KMT2ANPSR1 | |
| SCHEMBL1611020 | 0.89 | ALDH1A1 (0.31) | ALDH1A1PPARGMAPK10KMT2ANPSR1 | |
| SCHEMBL13212352 | 0.88 | ALDH1A1 (0.32) | ALDH1A1PPARGMAPK10KMT2ANPSR1 | |
| SCHEMBL16088864 | 0.88 | CHRNA7 (0.33) | ALDH1A1KMT2ACHRNA7HTR3A | |
| Hydrochloric Acid SCHEMBL7835718 | 0.88 | OPRK1 (0.31) | ALDH1A1PPARGMAPK10KMT2ANPSR1 | |
| Vosaroxin SCHEMBL674441 | 0.88 | HTR3A (0.35) | ALDH1A1PPARGMAPK10KMT2ANPSR1 | |
| Vosaroxin SCHEMBL195037 | 0.88 | HTR3A (0.35) | ALDH1A1PPARGMAPK10KMT2ANPSR1 | |
| Hydrochloric Acid SCHEMBL7835735 | 0.88 | OPRK1 (0.31) | ALDH1A1PPARGMAPK10KMT2ANPSR1 | |
| Vosaroxin SCHEMBL3207291 | 0.88 | HTR3A (0.35) | ALDH1A1PPARGMAPK10KMT2ANPSR1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 15 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8580814-B2 | Methods of using (+)-1,4-dihydro-7-[(3S,4S)-3-methoxy-4-(methylamino)-1-pyrrolidinyl]-4- oxo-1-(2-thiazolyl)-1,8-naphthyridine-3-carboxylic acid for treatment of cancer | SUNESIS PHARMACEUTICALS, INC. (US) | 2013-11-12 | — | — | US | disclosed |
| US-8518872-B2 | Methods of using (+)-1,4-dihydro-7-[(3S,4S)-3-methoxy-4-(methylamino)-1-pyrrolidinyl]-4-OXO-1-(2-thiazolyl)-1,8-naphthyridine-3-carboxylic acid in combination therapy | SUNESIS PHARMACEUTICALS, INC. (US) | 2013-08-27 | — | — | US | disclosed |
| US-8497282-B2 | Method of preparing (+)-1,4-dihydro-7-[(3S,4S)-3-methoxy-4-(methylamino)-1-pyrrolidinyl]-4-oxo-1-(2-thiazolyl)-1,8-naphthyridine-3-carboxylic acid | SUNESIS PHARMACEUTICALS, INC. (US) | 2013-07-30 | — | — | US | disclosed |
| US-8138202-B2 | Stable SNS-595 compositions and methods of preparation | SUNESIS PHARMACEUTICALS, INC. (US) | 2012-03-20 | — | — | US | disclosed |
| US-7968565-B2 | Therapeutic combinations comprising (+)-1,4-dihydro-7-[(3S,4S)-3-methoxy-4-(methylamino)-1-pyrrolidinyl]-4-oxo-1-(2-thiazolyl)-1,8-naphthyridine-3-carboxylic acid | SUNESIS PHARMACEUTICALS, INC. (US) | 2011-06-28 | — | — | US | disclosed |
| US-20110086876-A1 | STABLE SNS-595 COMPOSITIONS AND METHODS OF PREPARATION | SUNESIS PHARMACEUTICALS, INC. | 2011-04-14 | — | — | US | disclosed |
| US-20110082169-A1 | Stable SNS-595 Compositions and Methods of Preparation | SUNESIS PHARMACEUTICALS, INC. | 2011-04-07 | — | — | US | disclosed |
| US-20100297142-A1 | METHODS OF USING (+)-1,4-DIHYDRO-7-[(3S,4S)-3-METHOXY-4-(METHYLAMINO)-1-PYRROLIDINYL]-4-OXO-1-(2-THIAZOLYL)-1,8-NAPHTHYRIDINE-3-CARBOXYLIC ACID IN COMBINATION THERAPY | SUNESIS PHARMACEUTICALS, INC. | 2010-11-25 | — | — | US | disclosed |
| US-7829577-B2 | Voreloxin( SNS-595 ) and methanesulfonic acid ( for adjusting ph acidic) as anticarcinogenic agent | DAINIPPON SUMITOMO PHARMA CO., LTD. (JP) | 2010-11-09 | — | — | US | disclosed |
| US-20100203162-A1 | Method of preparing (+)-1,4-dihydro-7-[(3S,4S)-3-methoxy-4-(methylamino)-1-pyrrolidinyl]-4-oxo-1-(2-thiazolyl)-1,8-naphthyridine-3-carboxylic acid | SUNESIS PHARMACEUTICALS, INC. | 2010-08-12 | — | — | US | disclosed |
| US-20100203162-A1 | Method of preparing (+)-1,4-dihydro-7-[(3S,4S)-3-methoxy-4-(methylamino)-1-pyrrolidinyl]-4-oxo-1-(2-thiazolyl)-1,8-naphthyridine-3-carboxylic acid | SUNESIS PHARMACEUTICALS, INC. | 2010-08-12 | — | — | US | disclosed |
| US-20100048609-A1 | PHARMACEUTICAL DOSAGE FORMS FOR (+)-1,4-DIHYDRO-7-[(3S,4S)-3-METHOXY-4-(METHYLAMINO)-1-PYRROLIDINYL]-4-OXO-1-(2-THIAZOLYL)-1,8-NAPHTHYRIDINE-3-CARBOXYLIC ACID | SUNESIS PHARMACEUTICALS, INC. | 2010-02-25 | — | — | US | disclosed |
| US-20090263393-A1 | Methods of using(+)-1,4-dihydro-7-[(3s,4s)-3-methoxy-4-(methylamino)-1-pyrrolidinyl]-4 -oxo-1-(2-thiazolyl)- 1,8-naphthyridine-3-carboxylic acid for treatment of cancer | SUNESIS PHARMACEUTICALS, INC. | 2009-10-22 | — | — | US | disclosed |
| US-20090181377-A1 | HUMAN RIBOSOMAL DNA (rDNA) AND RIBOSOMAL RNA (rRNA) NUCLEIC ACIDS AND USES THEREOF | CYLENE PHARMACEUTICALS, INC. (US) | 2009-07-16 | — | — | US | disclosed |
| US-20070117770-A1 | Human ribosomal DNA (rDNA) and ribosomal RNA (rRNA) nucleic acids and uses thereof | CYLENE PHARMACEUTICALS, INC. (US) | 2007-05-24 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (8 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110082169-A1 | Stable SNS-595 Compositions and Methods of Preparation | NES, NCDN, NCL | ALDH1A1 3346/4885PPARG 3341/4885MAPK10 2861/4885 |
| US-20090263393-A1 | Methods of using(+)-1,4-dihydro-7-[(3s,4s)-3-methoxy-4-(methylamino)-1-pyrrolidinyl]-4 -oxo-1-(2-thiazolyl)- 1,8-naphthyridine-3-carboxylic acid for treatment of cancer | IL2, PBK, MALT1 | ALDH1A1 60/4885PPARG 81/4885MAPK10 3787/4885 |
| US-20100203162-A1 | Method of preparing (+)-1,4-dihydro-7-[(3S,4S)-3-methoxy-4-(methylamino)-1-pyrrolidinyl]-4-oxo-1-(2-thiazolyl)-1,8-naphthyridine-3-carboxylic acid | CYP7A1, MT-ND1, DNM1 | ALDH1A1 66/4885PPARG 690/4885MAPK10 4499/4885 |
| US-20100048609-A1 | PHARMACEUTICAL DOSAGE FORMS FOR (+)-1,4-DIHYDRO-7-[(3S,4S)-3-METHOXY-4-(METHYLAMINO)-1-PYRROLIDINYL]-4-OXO-1-(2-THIAZOLYL)-1,8-NAPHTHYRIDINE-3-CARBOXYLIC ACID | MLNR, SMN1; SMN2, MLN | ALDH1A1 273/4885PPARG 2111/4885MAPK10 3629/4885 |
| US-20110086876-A1 | STABLE SNS-595 COMPOSITIONS AND METHODS OF PREPARATION | NES, NCDN, NCL | ALDH1A1 3346/4885PPARG 3341/4885MAPK10 2861/4885 |
| US-20100297142-A1 | METHODS OF USING (+)-1,4-DIHYDRO-7-[(3S,4S)-3-METHOXY-4-(METHYLAMINO)-1-PYRROLIDINYL]-4-OXO-1-(2-THIAZOLYL)-1,8-NAPHTHYRIDINE-3-CARBOXYLIC ACID IN COMBINATION THERAPY | TYMP, TYMS, NCL | ALDH1A1 492/4885PPARG 1760/4885MAPK10 4013/4885 |
| US-20090181377-A1 | HUMAN RIBOSOMAL DNA (rDNA) AND RIBOSOMAL RNA (rRNA) NUCLEIC ACIDS AND USES THEREOF | NOP2, POLRMT, FBL | ALDH1A1 4046/4885PPARG 4751/4885MAPK10 4120/4885 |
| US-20070117770-A1 | Human ribosomal DNA (rDNA) and ribosomal RNA (rRNA) nucleic acids and uses thereof | NOP2, POLRMT, FBL | ALDH1A1 4046/4885PPARG 4751/4885MAPK10 4120/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.